Sign up UNITED KINGDOM
Proactive Investors - Run By Investors For Investors

Radius soars as Amgen sees mixed results for osteoporosis drug

Amgen's new osteoporosis treatment may not be as effective as a rival drug being developed by Radius.
Radius soars as Amgen sees mixed results for osteoporosis drug
Romo may generate sales of $1bn but faces competition from Radius’s experimental drug.

Shares in Radius Health (NASDAQ:RDUS) jumped by 27% as a rival osteoporosis treatment, romo, developed by Amgen (NASDAQ:AMGN) produced mixed results in a phase III trial.

The Amgen drug Romosozumab, or romo, achieved its primary endpoint of a significantly reduced risk of spinal fracture, but did not reduce breaks outside the spine area over longer period, its secondary endpoint.

Even so, Amgen and its Belgian partner UCB intend to file for regulatory approval later this year.

Analysts suggest Romo may generate sales of $1bn but faces competition from Radius’s experimental drug abaloparatide and also from an Eli Lily drug, Forteo, which comes off patent soon.

Abaloparatide reduced the risk of spinal fracture by 86% in its phase III trial compared to romo’s 73%, though it has to be injected daily compared to once a month with Amgen/UCB’s drug.

Amgen added that when combined over two years with Prolia, its current osteoporosis drug, the reduction rose to 75%.

Amgen said although Romo, designed to inhibit the protein sclerostin, reduced both spine and non-spine fractures in the first year, it did not repeat the performance in non-vertebral fractures in the second year.

Blocking sclerostin increases bone formation.

Shares in Amgen fell 2% to US$147.5 while Radius climbed US$7.24 to US$34.24.

View full RDUS profile View Profile

Related Articles

stem cell
June 12 2017
"With multiple value upside triggers ahead, including imminent maiden revenues from CellPlan, I very much look forward to the opportunities ahead" - CEO João Andrade
diagram of the human microbiome
September 13 2017
OptiBiotix is a pioneer in the human microbiome, which is essentially the bacteria that inhabits the gut and skin
1504120610_biotechLatest.jpg
August 31 2017
The company is poised for a milestone-rich period over the next year or so

© Proactive Investors 2017

Proactive Investor UK Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use